US0D1083977S

(12) United States Design Patent

Morelock

(10) Patent No.: US D1,083,977 S
(45) Date of Patent: ** Jul. 15, 2025

(54) **DISPLAY WITH GRAPHICAL USER INTERFACE FOR A WEARABLE SENSOR**

(71) Applicant: **Biolinq Incorporated**, San Diego, CA (US)

(72) Inventor: **David Michael Morelock**, Escondido, CA (US)

(73) Assignee: **Biolinq Incorporated**, San Diego, CA (US)

(**) Term: **15 Years**

(21) Appl. No.: **29/885,802**

(22) Filed: **Feb. 28, 2023**

(51) **LOC (15) Cl.** **14-04**

(52) **U.S. Cl.**
USPC **D14/485**

(58) **Field of Classification Search**
USPC D14/485–495
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,305,401	A	12/1981	Reissmueller et al.
4,323,996	A	4/1982	Ganter
4,407,295	A	10/1983	Steuer et al.
5,131,390	A	7/1992	Sakaguchi et al.
5,279,543	A	1/1994	Glikfeld et al.
5,286,364	A	2/1994	Yacynych et al.
5,540,828	A	7/1996	Yacynych
5,730,714	A	3/1998	Guy et al.
5,766,132	A	6/1998	Yasukawa et al.
6,036,055	A	3/2000	Mogadam et al.
6,139,718	A	10/2000	Kurnik et al.
6,269,053	B1	7/2001	Kawata et al.
6,284,126	B1	9/2001	Kurnik et al.
6,413,396	B1	7/2002	Yang et al.
6,471,903	B2	10/2002	Sherman et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CH	717520	A2	12/2021
CN	305781317	*	5/2020

(Continued)

OTHER PUBLICATIONS

Round Navigation, www.pngtree.com, By 588ku, retrieved Sep. 4, 2024, posted online Jun. 18, 2018 URL<:https://pngtree.com/freepng/round-navigation-icon_4752591.html (Year: 2018).*

(Continued)

Primary Examiner — Rachel A. Voorhies
Assistant Examiner — Gary N Chamberlin
(74) *Attorney, Agent, or Firm* — Cooley LLP

(57) **CLAIM**

The ornamental design for a display with graphical user interface for a wearable sensor, as shown and described.

DESCRIPTION

FIG. **1** is a front view showing a display with graphical user interface for a wearable sensor;
FIG. **2** is a front view thereof, shown in an alternate position;
FIG. **3** is a front view thereof, shown in an alternate position; and,
FIG. **4** is a front view thereof, shown in an alternate position.

The stippling represents a contrast in appearance. The outermost broken line is for the purpose of illustrating the display and forms no part of the claimed design. The remaining broken lines illustrate portions of the graphical user interface that form no part of the claimed design.

1 Claim, 4 Drawing Sheets



(56) **References Cited**

U.S. PATENT DOCUMENTS

D474,197	S *	5/2003	Nguyen	D14/486
6,603,987	B2	8/2003	Whitson	
6,814,845	B2	11/2004	Wilson et al.	
6,862,466	B2	3/2005	Ackerman	
6,908,453	B2	6/2005	Fleming et al.	
7,097,776	B2	8/2006	Govinda Raju	
7,132,054	B1	11/2006	Kravitz et al.	
7,262,068	B2	8/2007	Roy et al.	
7,310,544	B2	12/2007	Brister et al.	
7,343,188	B2	3/2008	Sohrab	
7,344,499	B1	3/2008	Prausnitz et al.	
D567,249	S	4/2008	Gunn et al.	
7,429,333	B2	9/2008	Chiou et al.	
7,456,112	B2	11/2008	Lee	
7,493,232	B1	2/2009	Surina	
D625,733	S *	10/2010	Anzures	D14/486
8,022,292	B2	9/2011	Arianpour et al.	
8,060,318	B2	11/2011	Vering et al.	
D651,613	S *	1/2012	Ouilhet	D14/491
8,088,321	B2	1/2012	Ferguson et al.	
8,094,009	B2	1/2012	Allen et al.	
8,125,331	B2	2/2012	Allen et al.	
8,130,095	B2	3/2012	Allen et al.	
8,280,475	B2	10/2012	Brister et al.	
8,284,046	B2	10/2012	Allen et al.	
8,574,165	B2	11/2013	Marsh	
D699,251	S *	2/2014	Rao	D14/486
D701,964	S	4/2014	Yoneta et al.	
8,750,955	B2	6/2014	Brister et al.	
8,798,799	B2	8/2014	Deo et al.	
8,909,543	B2	12/2014	Tropper et al.	
D722,697	S	2/2015	Moon et al.	
9,041,730	B2	5/2015	Johnson et al.	
9,055,901	B2	6/2015	Brister et al.	
9,107,623	B2	8/2015	Brauker et al.	
D744,529	S *	12/2015	Guzmán	D14/491
D745,046	S *	12/2015	Shin	D14/489
D750,786	S	3/2016	Davies et al.	
D757,000	S	5/2016	Lagomarsino et al.	
D760,277	S *	6/2016	Park	D14/489
D763,894	S *	8/2016	Lamparelli	D14/486
D771,824	S	11/2016	Minoli	
D773,529	S *	12/2016	Cabrera, Jr.	D14/490
D776,285	S	1/2017	Dinger	
9,551,698	B2	1/2017	Huys et al.	
D778,952	S *	2/2017	Kim	D14/489
D789,391	S *	6/2017	Cabrera, Jr.	D14/486
D794,801	S	8/2017	Newhouse et al.	
9,717,843	B2	8/2017	Grucela et al.	
9,737,247	B2	8/2017	Wang et al.	
9,743,870	B2	8/2017	Wang et al.	
D803,250	S *	11/2017	Lee	D14/488
D806,706	S	1/2018	Kim et al.	
D810,952	S	2/2018	Hsu	
D813,877	S *	3/2018	Hough	D14/485
D815,289	S	4/2018	Evers et al.	
D816,229	S	4/2018	Frick et al.	
9,933,387	B1	4/2018	McCanna et al.	
D820,988	S	6/2018	Pushpala et al.	
D821,571	S	6/2018	Stonecipher et al.	
10,004,435	B2	6/2018	Larvenz et al.	
10,029,043	B2	7/2018	Grucela et al.	
10,092,207	B1	10/2018	Windmiller	
D832,870	S *	11/2018	Hu	D14/486
D833,023	S	11/2018	Maletic	
10,136,846	B2	11/2018	Wang et al.	
D842,996	S	3/2019	Frick et al.	
D845,289	S	4/2019	Chuang et al.	
10,251,565	B2	4/2019	Chan et al.	
D850,626	S	6/2019	Gardner et al.	
10,321,859	B1	6/2019	Wynbrandt et al.	
D853,382	S	7/2019	Haigh	
10,362,973	B2	7/2019	Hernandez-Rosas et al.	
D864,985	S *	10/2019	Kim	D14/492
D864,993	S *	10/2019	Kim	D14/488
D867,911	S	11/2019	Alabdin	
D870,291	S	12/2019	Barry et al.	
10,492,708	B1	12/2019	Windmiller	
D873,294	S *	1/2020	Anzures	D14/488
D875,106	S *	2/2020	Winton	D14/485
D875,254	S	2/2020	Cooke et al.	
D882,432	S	4/2020	Yee et al.	
D888,731	S *	6/2020	Momchilov	D14/485
10,765,369	B2	9/2020	Antonio et al.	
D898,924	S	10/2020	Hinds et al.	
D903,877	S	12/2020	Pace et al.	
11,039,767	B2	6/2021	Hayter	
11,045,142	B1	6/2021	Windmiller et al.	
D928,150	S	8/2021	Maruyama et al.	
11,087,868	B2	8/2021	Budiman	
11,102,306	B2	8/2021	Mensinger et al.	
D929,990	S	9/2021	Maruyama et al.	
D931,467	S	9/2021	Golda et al.	
11,141,116	B2	10/2021	Cabrera, Jr. et al.	
11,150,145	B2	10/2021	Nekoomaram et al.	
11,154,253	B2	10/2021	Cabrera, Jr. et al.	
11,182,332	B2	11/2021	Anderson et al.	
11,197,626	B2	12/2021	Koehler et al.	
11,205,511	B2	12/2021	Hayter et al.	
11,207,025	B1	12/2021	Trapero et al.	
11,272,890	B2	3/2022	McGarraugh	
11,305,906	B2	4/2022	Grucela et al.	
D951,972	S *	5/2022	Vincent	D14/486
11,317,867	B2	5/2022	Garai et al.	
D954,744	S *	6/2022	Feitosa	D14/491
11,357,430	B2	6/2022	Pushpala et al.	
11,373,347	B2	6/2022	Kamath et al.	
D957,438	S	7/2022	Hayter et al.	
D958,184	S *	7/2022	Page	D14/489
D958,817	S	7/2022	Mensinger et al.	
11,389,088	B2	7/2022	Desborough et al.	
D960,895	S	8/2022	Mensinger	
D960,913	S *	8/2022	Kiikkala	D14/485
D962,446	S	8/2022	Bernstein et al.	
11,406,331	B2	8/2022	Budiman	
11,406,818	B2	8/2022	Windmiller	
11,437,141	B2	9/2022	Mensinger et al.	
11,446,108	B2	9/2022	Larson et al.	
D967,128	S	10/2022	Kumar et al.	
D967,136	S	10/2022	Kumar et al.	
11,464,459	B2	10/2022	Sjolund et al.	
11,475,988	B1	10/2022	Burkart et al.	
11,478,194	B2	10/2022	Windmiller et al.	
11,497,422	B2	11/2022	Koehler et al.	
11,507,530	B2	11/2022	Anderson et al.	
11,517,222	B2	12/2022	Pushpala et al.	
11,534,089	B2	12/2022	Taub et al.	
D977,116	S	1/2023	Gennaco et al.	
11,547,799	B2	1/2023	Zhong et al.	
D978,178	S *	2/2023	Lamb	D14/486
D978,357	S	2/2023	Zysk et al.	
11,576,600	B2	2/2023	Lee et al.	
11,654,270	B2	5/2023	Mansfield, III et al.	
11,660,392	B2	5/2023	Kamen et al.	
D988,160	S	6/2023	Morelock	
11,672,965	B2	6/2023	Mansfield et al.	
D996,999	S	8/2023	Morelock	
D1,004,105	S	11/2023	Zysk et al.	
D1,006,265	S	11/2023	Quitter et al.	
D1,006,266	S	11/2023	Quitter et al.	
D1,010,133	S	1/2024	Yee et al.	
D1,012,292	S	1/2024	Armstrong et al.	
D1,012,744	S	1/2024	Morelock	
11,857,344	B2	1/2024	Windmiller et al.	
11,872,055	B2	1/2024	Tangney et al.	
D1,013,544	S	2/2024	Morelock	
11,904,127	B2	2/2024	Mansfield et al.	
11,963,796	B1	4/2024	Windmiller et al.	
11,986,614	B2	5/2024	Mansfield et al.	
12,011,294	B2	6/2024	Campbell et al.	
D1,033,641	S	7/2024	Morelock	
D1,035,004	S	7/2024	Morelock	
D1,035,670	S *	7/2024	Vanderhill	D14/485
D1,038,794	S	8/2024	Morelock	

(56) **References Cited**

U.S. PATENT DOCUMENTS

D1,040,171	S *	8/2024	Chen	D14/485
12,070,313	B2	8/2024	Fuchs et al.	
12,109,032	B1	10/2024	Windmiller et al.	
D1,051,745	S	11/2024	Morelock	
D1,057,153	S	1/2025	Morelock	
2003/0225360	A1	12/2003	Eppstein et al.	
2006/0015061	A1	1/2006	Kuo et al.	
2007/0170054	A2	7/2007	Wilsey	
2007/0213044	A1	9/2007	Steingart et al.	
2009/0088652	A1	4/2009	Tremblay	
2009/0143761	A1	6/2009	Cantor et al.	
2009/0259118	A1	10/2009	Feldman et al.	
2010/0056873	A1	3/2010	Allen et al.	
2010/0286803	A1	11/2010	Tillotson et al.	
2012/0323097	A9	12/2012	Chowdhury	
2013/0065257	A1	3/2013	Wang et al.	
2013/0144131	A1	6/2013	Wang et al.	
2014/0259652	A1	9/2014	Pushpala et al.	
2014/0275897	A1	9/2014	Pushpala et al.	
2014/0336487	A1	11/2014	Wang et al.	
2015/0335272	A1	11/2015	Natale et al.	
2015/0351689	A1	12/2015	Adams et al.	
2017/0003766	A1	1/2017	Budiman	
2017/0055851	A1	3/2017	Al-Ali	
2017/0215774	A1	8/2017	Koehler et al.	
2017/0290532	A1	10/2017	Antonio et al.	
2018/0042559	A1	2/2018	Cabrera, Jr. et al.	
2018/0116572	A1	5/2018	Simpson et al.	
2018/0249937	A1	9/2018	Wiese et al.	
2018/0295897	A1	10/2018	Donohoe et al.	
2019/0095602	A1	3/2019	Setlak et al.	
2019/0125223	A1	5/2019	Wang et al.	
2019/0133638	A1	5/2019	Il et al.	
2019/0167167	A1	6/2019	Mitchell et al.	
2019/0246914	A1	8/2019	Constantin et al.	
2019/0246973	A1	8/2019	Constantin et al.	
2019/0274603	A1	9/2019	Ringemann	
2019/0307376	A1	10/2019	Hernandez-Rosas et al.	
2019/0309433	A1	10/2019	Sattayasamitsathit et al.	
2020/0085341	A1	3/2020	Windmiller	
2020/0101286	A1	4/2020	Windmiller et al.	
2020/0146598	A1	5/2020	Mayou et al.	
2020/0214566	A1	7/2020	Allen et al.	
2020/0245914	A1	8/2020	Bhavaraju et al.	
2020/0254240	A1	8/2020	Windmiller et al.	
2020/0275870	A1	9/2020	Bhavaraju et al.	
2020/0297997	A1	9/2020	Windmiller et al.	
2020/0337615	A1	10/2020	Larvenz et al.	
2021/0113132	A1	4/2021	Bhagat et al.	
2021/0161436	A1	6/2021	Troncelliti et al.	
2021/0169384	A1	6/2021	Taub et al.	
2021/0187286	A1	6/2021	Windmiller et al.	
2021/0196162	A1	7/2021	Halac et al.	
2021/0236057	A1	8/2021	Pushpala et al.	
2021/0282672	A1	9/2021	Kumar et al.	
2021/0321914	A1	10/2021	Brister et al.	
2021/0335499	A1	10/2021	Simpson et al.	
2021/0345894	A1	11/2021	Maceachern et al.	
2021/0361199	A1	11/2021	Kumar	
2021/0378601	A1	12/2021	Kumar et al.	
2021/0393201	A1	12/2021	Morelock et al.	
2022/0000399	A1	1/2022	Hayter et al.	
2022/0000432	A1	1/2022	Cabrera, Jr. et al.	
2022/0031209	A1	2/2022	Windmiller et al.	
2022/0031244	A1	2/2022	Windmiller et al.	
2022/0057868	A1	2/2022	Budiman	
2022/0080678	A1	3/2022	Cole et al.	
2022/0087610	A1	3/2022	Pushpala et al.	
2022/0095930	A1	3/2022	Li et al.	
2022/0101995	A1	3/2022	Johnson et al.	
2022/0142524	A1	5/2022	Harper et al.	
2022/0142589	A1	5/2022	Lee	
2022/0175278	A1	6/2022	Campbell et al.	
2022/0194644	A1	6/2022	Grucela et al.	
2022/0202319	A1	6/2022	Crawford et al.	
2022/0202320	A1	6/2022	Diener et al.	
2022/0216735	A1	7/2022	Yan et al.	
2022/0265224	A1	8/2022	Hauptman et al.	
2022/0283042	A1	9/2022	Nekoomaram et al.	
2022/0292746	A1	9/2022	Kamath et al.	
2022/0336100	A1	10/2022	Chiu et al.	
2022/0361825	A1	11/2022	Kang	
2022/0370011	A1	11/2022	Windmiller et al.	
2022/0392643	A1	12/2022	Mensinger et al.	
2023/0005588	A1	1/2023	Sokolovskyy et al.	
2023/0074798	A1	3/2023	Tangney et al.	
2023/0094419	A1	3/2023	Mansfield, III et al.	
2023/0099617	A1	3/2023	Mansfield, III et al.	
2023/0137258	A1	5/2023	Windmiller	
2023/0190147	A1	6/2023	Campbell et al.	
2023/0256220	A1	8/2023	Mansfield, III et al.	
2023/0301552	A1	9/2023	Mallires et al.	
2023/0310823	A1	10/2023	Mansfield et al.	
2023/0414102	A1	12/2023	Allen et al.	
2024/0008777	A1	1/2024	Fuchs et al.	
2024/0081740	A1	3/2024	Windmiller et al.	
2024/0164719	A1	5/2024	Campbell et al.	
2024/0252115	A1	8/2024	Tangney et al.	
2024/0315614	A1	9/2024	Campbell et al.	
2024/0341636	A1	10/2024	Yang et al.	
2024/0366125	A1	11/2024	Alonso-Soski et al.	
2024/0382157	A1	11/2024	Windmiller et al.	
2024/0408366	A1	12/2024	Mansfield et al.	
2024/0423526	A1	12/2024	Windmiller et al.	
2025/0000395	A1	1/2025	Brister et al.	

FOREIGN PATENT DOCUMENTS

CN	306169676		11/2020
CN	306260908		1/2021
CN	306893408	*	10/2021
CN	307293994	*	4/2022
CN	307384488	*	6/2022
CN	307672333		11/2022
CN	308050427		5/2023
EM	001371280-0001		6/2013
EP	3871602 A1		9/2021
FR	3042872 B1		12/2020
GB	06192168		2/2022
JP	1721016 S		7/2022
KR	2013502603	*	11/2014
WO	WO-2009034313 A2		3/2009
WO	WO-2009034313 A3		3/2009
WO	WO-2009064164 A2		5/2009
WO	WO-2009064164 A3		5/2009
WO	WO-2010107913 A2		9/2010
WO	WO-2010120364 A2		10/2010
WO	WO-2010120364 A3		10/2010
WO	WO-2012020332 A2		2/2012
WO	WO-2012020332 A3		2/2012
WO	WO-2013058879 A2		4/2013
WO	WO-2013058879 A3		4/2013
WO	WO-2020073060 A1		4/2020
WO	WO-D214300002		5/2021
WO	WO-2021148596 A1		7/2021
WO	WO-2022044017 A1		3/2022
WO	WO-2022031792 A9		4/2022
WO	WO-2022044018 A3		4/2022
WO	WO-2022266443 A1		12/2022
WO	WO-2023055755 A1		4/2023
WO	WO-2023064877 A1		4/2023
WO	WO-2023133468 A1		7/2023
WO	WO-2023229662 A2		11/2023
WO	WO-2024010827 A1		1/2024
WO	WO-2024163950 A2		8/2024
WO	WO-2024238798 A1		11/2024

OTHER PUBLICATIONS

Dexcom, www.diabetesstrong.com, By Christel Oerum, MS, retrieved online Sep. 4, 2024, posted online Apr. 20, 2020 URL<:http://web.archive.org/web/20200420123603/https://diabetesstrong.com/dexcom-cgm-trend-arrows/ (Year: 2020).*

(56) **References Cited**

OTHER PUBLICATIONS

Blue Circle, www.instagram.com, By bluecirclediabetesfoundation, retrieved Sep. 4, 2024, posted online Jan. 12, 2020 URL<:https://www.instagram.com/p/B7OINIHBIAD/?utm_source=ig_embed&utm_campaign=loading (Year: 2020).*
AiDEX, www.appadvice.com, retrieved online Sep. 4, 2024, posted online Nov. 9, 2022 URL<:https://appadvice.com/app/wellion-aidex-sensor-mmol-l/6444144767 (Year: 2022).*
Abbot press release (2020). "New late-breaking data show use of Abbott's Freestyle® Libre System significantly reduces HBA1C levels in people with type 2 diabetes using insulin or not," 3 pages.
Al Hayek et al., "Patient Satisfaction and Clinical Efficacy of Novel Blood Glucose Meters Featuring Color Range Indicators in Patients With Type 2 Diabetes: A Prospective Study" Cureus Oct. 27, 2020; 12(10):e11195. 8 pages. doi:10.7759/cureus.11195.
Allen et al., "Continuous glucose monitoring counseling improves physical activity behaviors of individuals with type 2 diabetes: A randomized clinical trial" Diabetes Res Clin Pract. Jun. 2008; 80(3): 371-379. doi:10.1016/j.diabres.2008.01.006.
American Diabetes Association® Press Release (2020). "American Diabetes Association ® Applauds policymakers' Focus on Addressing High Costs of Insulin for Seven Million Americans," 4 pages.
Bantle, J.P et al. (1997). "Glucose measurement in patients with diabetes mellitus with dermal interstitial fluid," J. Lab. Clin. Med. 130:436-441.
Barrett et al., "Risk for Newly Diagnosed Diabetes 30 Days After SARS-CoV-2 Infection Among Persons Aged 18 Years—United States, Mar. 1, 2020-Jun. 28, 2021" MMWR Morb Mortal Wkly Rep. Jan. 14, 2022; 71(2):59-65. doi:10.15585/mmwr.mm7102e2.
Beckles, G.L. et al. (2016). "Disparities in the prevalence of diagnosed diabetes—United States, 1999-2002 and 2011-2014," MMWR 65:1265-1269.
Biolinq, Inc. (2019). The Intelligent Continuous Glucose Monitoring System, 5 total pages.
Cao, J. et al. (2017). "Validation of capillary blood analysis and capillary testing mode on the epoc Point of Care system," Pract. Lab. Med. 9:24-27.
Castle, J.R. et al. (2012). "The accuracy benefit of multiple amperometric glucose sensors in people with type 1 diabetes," Diabetes Care 35:706-710.
Centers for Disease Control, "National Diabetes Statistics Report 2020 Estimates of Diabetes and Its Burden in the United States" (2020) 32 pages.
Dexcom (2020). Analyst Day Presentation, 27 total pages.
Diabetes Care (2021). "7. Diabetes Technology: Standards of Medical Care in Diabetes—2021," Diabetes Care 44(Supplement 1):S85-S99.
Dunkin et al., "Scarring occurs at a critical depth of skin injury: precise measurement in a graduated dermal scratch in human volunteers" Plast Reconstr Surg. May 2007; 119(6):1722-1732. doi: 10.1097/01.prs.0000258829.07399.f0.
Ehrhardt et al., "Behavior Modification in Prediabetes and Diabetes: Potential Use of Real-Time Continuous Glucose Monitoring" Journal of Diabetes Science and Technology Mar. 2019; 13(2):271-275.
Ehrhardt et al., "Continuous Glucose Monitoring As a Behavior Modification Tool" Clin Diabetes. Apr. 2020; 38(2):126-131. doi: 10.2337/cd19-0037.
Ehrhardt et al., "The Effect of Real-Time Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Mellitus" Journal of Diabetes Science and Technology May 2011; 5(3):668-675.
Fang, M. et al. (2021). "Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018," N. Engl. Med. 384:2219-2228.
Fonda et al., "The Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes" Journal of Diabetes Science and Technology (2016) 10(4):898-904.
French, D.P. et al. (2008). "Original Article: Psychological Care Self-monitoring of blood glucose changed non-insulin-treated Type 2 diabetes patients' beliefs about diabetes and self-monitoring in a randomized trial," Diav. Med. 25:1218-1228.
Grady, M. et al. (2017). "Examining the Impact of a Novel Blood Glucose Monitor with Color Range Indicator on Decision-Making in Patients With Type 1 and Type 2 Diabetes and its Association With Patient Numeracy Level," JMIR Diabetes 2:e24. 11 pages.
Grady, M. et al. (2018). "Use of Blood Glucose Meters Featuring Color Range Indicators Improves Glycemic Control in Patients with Diabetes in Comparison to Blood Glucose Meters Without Color (Accents Study)," J. Diab. Sci. Tech. 12:1211-1219.
Groenendaal, W. et al. (2008). "Modeling Glucose and Water Dynamics in Human Skin," Diab. Tech. Therap. 10:283-293.
Han et al., "The End of the Road for the YSI 2300 Analyzer: Where Do We Go Now?" Journal of Diabetes Science and Technology (2020) 14(3):595-600.
Han et al., "The YSI 2300 Analyzer Replacement Meeting Report" Journal of Diabetes Science and Technology (2020) 14(3):679-686.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2008). "Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes," N. Engl. Med. 359:1464-1476.
Karter, A.J. et al. (2021). "Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes," JAMA 325:2273-2284.
Martens, T. et al. (2021). "Effect of Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Treated with Basal Insulin A Randomized Clinical Trial," JAMA 325:2262-2272.
McClatchey, P.M. et al. (2019). "Fibrotic Encapsulation Is the Dominant Source of Continuous Glucose Monitor Delays," Diabetes 68:1892-1901.
Neerken, S. et al. (2004). "Characterization of age-related effects in human skin: A comparative study that applies confocal laser scanning microscopy and optical coherence tomography," J. Biomed. Optics 9:274-281.
Non-Final Office Action mailed on Nov. 14, 2019, for U.S. Appl. No. 29/650,794, filed Jun. 8, 2018, 10 pages.
Notice of Allowance mailed on Dec. 18, 2019, for U.S. Appl. No. 29/650,794, filed Jun. 8, 2018, 7 pages.
Notice of Allowance mailed on Sep. 29, 2022, for U.S. Appl. No. 29/774,399, filed Mar. 16, 2021, 7 pages.
Notice of Allowance mailed on Jan. 25, 2023, for U.S. Appl. No. 29/774,399, filed Mar. 16, 2021, 11 pages.
Notice of Allowance mailed on Mar. 1, 2023, for U.S. Appl. No. 29/815,797, filed Nov. 16, 2021, 10 pages.
Notice of Allowance mailed on May 17, 2023, for U.S. Appl. No. 29/836,984, filed Apr. 29, 2022, 7 pages.
Notice of Allowance mailed on May 31, 2023, for U.S. Appl. No. 29/838,870, filed May 16, 2022, 7 pages.
Notice of Allowance mailed on Jun. 14, 2023, for U.S. Appl. No. 29/815,797, filed Nov. 16, 2021, 9 pages.
Polonsky, W.H. et al. (2011). "A survey of blood glucose monitoring in patients with type 2 diabetes: Are recommendations from health care professionals being followed?" Curr. Med. Res. & Opinion 27:31-37.
Rigla, M. et al. (2018). "Human Subcutaneous Tissue Response to Glucose Sensors: Macrophages Accumulation Impact on Sensor Accuracy," Diabetes Technology & Therapeutics 20:296-302.
Sharifi et al., "Redundancy in Glucose Sensing: Enhanced Accuracy and Reliability of an Electrochemical Redundant Sensor for Continuous Glucose Monitoring" Journal of Diabetes Science and Technology (2016) 10(3):669-678.
Sheikh, Z. et al. (2015). "Macrophages, Foreign Body Giant Cells and Their Response to Implantable Biomaterials," Materials 8:5671-5701.
Shi, T. et al. (2016). "Modeling and Measurement of Correlation between Blood and Interstitial Glucose Changes," J. Diab. Res. Volume 2016, 9 pages.
Turner et al., "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)" The Lancet Sep. 1998; 352(9131):837-853.

(56) **References Cited**

OTHER PUBLICATIONS

Vigersky et al., "Short- and Long-Term Effects of Real-Time Continuous Glucose Monitoring in Patients with Type 2 Diabetes" Diabetes Care Jan. 2012; 35:32-38.
Wolicki et al., "Epidemiology and Prevention of Vaccine-Preventable Diseases: Chapter 6: Vaccine Administration" Centers for Disease Control and Prevention (2021) 17 pages.
World Health Organization, "Diabetes", Sep. 16, 2022, 5 pages.
Young et al., "Glucose Self-monitoring in Non-Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings: A Randomized Trial" JAMA Intern Med. Jul. 2017; 177(7):920-929.
Notice of Allowance mailed on Nov. 22, 2023, for U.S. Appl. No. 29/838,870, filed May 16, 2022, 7 pages.
Notice of Allowance mailed on Nov. 29, 2023, for U.S. Appl. No. 29/836,984, filed Apr. 29, 2022, 7 pages.
Abbott, Abbott's Freestyle® Libre 3 System Receives CE Mark, Published on: Sep. 28, 2020, PRNewswire.com, Retrieved from Internet: https://www.prnewswire.com/news-releases/abbotts-freestyle-libre-3-system-receives-ce-mark--features-worlds-smallest-thinnest-sensor-with-best-in-class-performance-at-the-same-low-cost-for -people-with-diabetes-301138719.html, 2 pages.
American Diabetes Association, "Diabetes and Emotional Health: A Practical Guide for Health Professionals Supporting Adults with Type 1 and Type 2 Diabetes" U.S. Edition (2021), 214 pages.
American Diabetes Association Professional Practice Committee, "6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2024" Diabetes Care Jan. 1, 2024; 47(Suppl 1):S111-S125.
American Diabetes Association Professional Practice Committee, "7. Diabetes Technology: Standards of Medical Care in Diabetes-2022" Diabetes Care Jan. 1, 2022; 45(Suppl 1):S97-S112.
Biolinq, "Biolinq Announces Results from First-in-Man Clinical Studies Showing Feasibility of a Novel, Minimally Invasive Approach to Continuous Glucose Monitoring in the Dermis" Published on: Jun. 15, 2020, PRNewswire.com, Retrieved from Internet https://www.prnewswire.com/news-releases/biolinq-announces-results-from-first-in-man-clinical-studies-showing-feasibility-of-a-novel-minimally-invasive-approach-to-continuous-glucose-monitoring-in-the-dermis-301076992. html, 3 pages.
Centers for Disease Control, "National Diabetes Statistics Report" May 2024, 16 pages.
Delve, Dexcom G6, Published in: 2019, Designdirectory.com, Retrieved from Internet: https://www.designdirectory.com/delve/Dexcom-G6? AspxAutoDetectCookieSupport=1 (Year: 2019), 3 pages.
Diabetes Control and Complications Trial Research Group, "The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus" N Engl J Med Sep. 30, 1993; 329(14):977-986.
Diabetes.co.uk, "FDA approves new CGM the Abbott FreeStyle Libre Pro System" Published on: Sep. 29, 2016, diabetes.co.uk, Retrieved from Internet: https://www.diabetes.co.uk/news/2016/sep/fda-approves-new-cgm-the-abbott-freestyle-libre-pro-system-90611033.html (Year: 2016), 2 pages.
Elsayed et al., "2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023" Diabetes Care Jan. 1, 2023; 46(Suppl 1):S19-S40.
Garg et al., "Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes", Published on: May 31, 2022, Diabetes Technology & Therapeutics, Retrieved from Internet: https://www.liebertpub.com/doi/10.1089/dia.2022.0011 (Year: 2022), 2 pages.
Idrus, "Medtronic integrates CGM, Fitbit data into mobile app" Published on: Dec. 19, 2016, Fierce Biotech.com, Retrieved from Internet : https://www.fiercebiotech.com/medical-devices/medtronic-integrates-cgm-fitbit-data-into-mobile-app (Year: 2016), 1 page.
Mendes-Soares et al., "Assessment of a Personalized Approach to Predicting Postprandial Glycemic Responses to Food Among Individuals Without Diabetes" JAMA Network Open Feb. 1, 2019; 2(2):e188102. 13 pages.
Miller et al., "Hypoglycemia in patients with type 2 diabetes mellitus" Arch Intern Med Jul. 9, 2001; 161(13):1653-1659.
Newton et al., "Diabetic ketoacidosis in type 1 and type 2 diabetes mellitus: clinical and biochemical differences" Arch Intern Med Sep. 27, 2004; 164(17):1925-1931.
Non-Final Office Action for U.S. Appl. No. 29/876,134 mailed Dec. 6, 2024, 18 pages.
Non-Final Office Action for U.S. Appl. No. 29/890,886 dated Mar. 28, 2024, 11 pages.
Notice of Allowance for U.S. Appl. No. 29/871,863 dated Feb. 26, 2024, 10 pages.
Notice of Allowance for U.S. Appl. No. 29/885,801 mailed Nov. 22, 2024, 10 pages.
Notice of Allowance for U.S. Appl. No. 29/890,886 mailed Jul. 15, 2024, 7 pages.
Notice of Allowance for U.S. Appl. No. 29/919,992 dated Mar. 28, 2024, 8 pages.
PRNewswire L'Oreal Unveils Prototype First-Ever Wearable Microfluidic Sensor, posted Jan. 6, 2019[online], [retrieved Jul. 2, 2024]. Retrieved from internet,https://www.prnewswire.com/news-releases/loreal-unveils-prototype-of-first-ever-wearable-microfluidic-sensor-to-measure-skin-ph-levels-300773342.html (Year: 2019), 11 pages.
Roche Diabetes Care, Roche Diabetes Carey Senseonics anuncian un acuerdo de distribuci6n para el sistema Eversense® CGM, Published on: May 26, 2016, PRNewswire.com, Retrieved from Internet: https://www.prnewswire.com/news-releases/roche-diabetes-care-y-senseonics-anuncian-un-acuerdo-de-distribucion-para-el-sistema-eversense-cgm-580978821.html, 1 page.
Segel et al., "Hypoglycemia-associated autonomic failure in advanced type 2 diabetes" Diabetes Mar. 2002; 51(3):724-733.
Shivers et al., "Turn it off!: diabetes device alarm fatigue considerations for the present and the future" J Diabetes Sci Technol May 1, 2013; 7(3): 789-794.
Springer Link Microneedle-Based Sensor Systems for Real-Time Continuous Transdermal Monitoring of Analytes in Body Fluids, posted May 11, 2019 [online], [retrieved Jul. 2, 2024]. Retrieved from internet, https://link.springer.com/chapter/10.1007/978-3-030-17971-7_26 (Year: 2019), 23 pages.
Tanenbaum et al., "Diabetes Device Use in Adults With Type 1 Diabetes: Barriers to Uptake and Potential Intervention Targets" Diabetes Care Feb. 2017 40(2):181-187.
UK Prospective Diabetes Study (UKPDS) Group, "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)" Lancet Sep. 12; 1998; 352(9131):837-853.
WaveForm Technologies Inc., "WaveForm Technologies Inc. Awarded CE Mark Approval for Their Continuous Glucose Monitoring System" Published on: Nov. 5, 2019, PRNewswire.com, Retrieved from Internet https://www.prnewswire.com/news-releases/waveform-technologies-inc-awarded-ce-mark-approval-for-their-continuous-glucose-monitoring-system-300952002.html, 1 page.

* cited by examiner



FIG. 1



FIG. 2



FIG. 3



FIG. 4